A drug currently under clinical development for Type 2 diabetes produced "meaningful" reductions in blood sugar, according to results of a late-stage clinical study.
A combination of two insulins made by Novo Nordisk reduced abnormally low blood sugar in diabetes patients, according to study results presented at a medical conference.
Obese diabetes patients could experience weight loss when taking Vivus' anti-obesity drug, according to an oral presentation at the International Diabetes Federation's World Diabetes Congress in Dubai.